Production and Characterization of a Novel OX40 Ligand for Clinical Use
Abstract
The goals of the second year/phase of the DOD funded research, PC073499, have been accomplished. We produced two human versions of the OX40 ligand:trimer:Ig protein. The two protein constructs have different human trimer domains (TRAF2 and Matrillin-4), which confer differing folding patterns within the two-dimension structure of the protein. These two fully human OX40L:Ig fusion proteins were administered to non-human primates to test for in vivo activity. The OX40L:Ig fusion proteins showed potent biologic activity in vivo, but it was clear that the one with the TRAF2 trimer domain was superior. Therefore we are moving forward with OX40L:Ig fusion protein with the TRAF2 trimer domain with the ultimate hope of taking it to clinical trials in patients with prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2010
- Accession Number
- ADA542444
Entities
People
- Andrew D. Weinberg